4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Nanotherapeutics to Treat Antibiotic Resistant Gram-Negative Pneumonia Infections (PNEUMONP)
Date du début: 1 janv. 2014, Date de fin: 31 déc. 2017,
The main objective of PneumoNP is the development of a theragnostic system for the treatment of lung Gram-negative bacterial infections. As a proof of concept PneumoNP will focus the attention on Klebsiella pneumoniae caused infections. A diagnostic kit will be developed to enable a rapid and precise identification of the bacteria strain causing the infection and avoid the use of wide spectrum a ...
Voir le projet
11
Participants partenaires
TERMINÉ
European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Voir le projet
29
Participants partenaires
TERMINÉ
IMmune MOdulating strategies for treatment of MErkel cell Carcinoma (IMMOMEC)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,
"Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer of the skin associated with the recently discovered, common Merkel cell polyomavirus (MCV). With an incidence of 0.44 per 100,000 MCC is a very rare cancer. Notably, however, although MCC is 40 times less common than malignant melanoma, MCC has a dramatically higher mortality rate than melanoma rendering MCC to ...
Voir le projet
11
Participants partenaires
TERMINÉ
Profiling Responders In Antibody Therapies (PRIAT)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2014,
"Therapeutic antibodies are the largest and fastest growing class of pharmaceutical biotechnology products, with annual sales above 30 billion US$. In some cases, antibody products have revolutionized the management of patients, e.g. TNF-blocking antibodies in Arthritis or Rituxan in lymphoma. However, for most antibody therapies, only a subset of patients benefit from treatment. Thus, there is an ...
Voir le projet